Following tamoxifen, aminoglutethimide was investigated as an anti-aromatase adjuvant treatment for early breast cancer, laying the first steps for aromatase inhibitors (AIs) [3] AIs are a revolutionary class of drugs that work by interrupting the production of oestrogen that can promote tumour growth in post-menopausal women. This evidence concerns the gene CYP19A1 and neoplasm.